Mouse CLEC12A / MICL / CLL-1 Protein, His Tag

Catalog # CLA-M5244

Synonym

CLEC12A,MICL,CLL-1,CLL1,DCAL2,DCAL-2,CD371

Source

Mouse CLEC12A, His Tag (CLA-M5244) is expressed from human 293 cells (HEK293). It contains AA Tyr 65 - Arg 267 (Accession # Q504P2-1).
Predicted N-terminus: His

Molecular Characterization



This protein carries a polyhistidine tag at the N-terminus.

The protein has a calculated MW of 25.7 kDa. The protein migrates as 30-40 kDa under reducing (R) condition (SDS-PAGE).

Endotoxin

Less than 1.0 EU per μg by the LAL method.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



Mouse CLEC12A, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

Background

CLEC12A (C-type lectin domain family 12 member A) is also known as CLL1, DCAL2, MICL. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Cell surface receptor that modulates signaling cascades and mediates tyrosine phosphorylation of target MAP kinases. Evidence of distinct disease propagating stem cells in myelodysplastic syndrome (MDS) has emerged in recent years. The role of CLEC12A in MDS, however, remains to be elucidated. Furthermore, CLEC12A has been proposed as a promising marker of leukaemic stem cells in AML.

References

(1) Toft-Petersen M, et al. 2016. Br J Haematol. 175(3):393-401.

(2) Neumann K, et al. 2014. Immunity. 40(3):389-99.

(3) Chen CH, et al. 2006. Blood. 107(4):1459-67.

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.